U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 4 of 4 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Oxiperomide was developed as a dopamine-receptor antagonist. Clinical trials have shown that this drug decreased dyskinesia in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Tomelukast (previously known as LY171883), an orally active antagonist of the CysLT1 receptor (leukotriene D4), which was investigated to treat asthma, but this study was discontinued because of adverse gastrointestinal effect.
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Tomelukast (previously known as LY171883), an orally active antagonist of the CysLT1 receptor (leukotriene D4), which was investigated to treat asthma, but this study was discontinued because of adverse gastrointestinal effect.